<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056589</url>
  </required_header>
  <id_info>
    <org_study_id>F13-1663</org_study_id>
    <nct_id>NCT00056589</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency</brief_title>
  <official_title>A Phase 1 Escalating Dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor XIII Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial was conducted in the United States of America (USA). The aim of this trial was to
      investigate safety and pharmacokinetics of escalating single doses of catridecacog
      (recombinant factor XIII, rFXIII) in patients with congenital factor XIII deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Days 0-28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes from baseline in physical examination or laboratory measurements</measure>
    <time_frame>Days 0-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rFXIII antibodies, as measured by ELISA (Enzyme-Linked Immuno Sorbent Assay)</measure>
    <time_frame>Days 0-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of yeast antibodies</measure>
    <time_frame>Days 0-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FXIII activity measured by the BerichromÂ® assay</measure>
    <time_frame>Days 0-28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Congenital FXIII Deficiency</condition>
  <arm_group>
    <arm_group_label>rFXIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>catridecacog</intervention_name>
    <description>Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).</description>
    <arm_group_label>rFXIII</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documental congenital FXIII deficiency

          -  Normal platelet count and clotting parameters

          -  Adequate renal and hepatic function

          -  If female and of child-bearing potential, negative serum pregnancy test within 7 days
             of enrollment

          -  If a sexually active male or a sexually active female of child-bearing potential,
             agreement to use a medically accepted form of contraception from the time of
             enrollment to completion of all follow-up study visits

          -  Negative drug and alcohol screens

        Exclusion Criteria:

          -  Received blood products or FXIII concentrates within 4 weeks of study enrollment

          -  Known antibodies to FXIII

          -  Hereditary or acquired coagulation disorder other than FXIII deficiency

          -  Previous history of autoimmune disorders involving autoantibodies e.g., systemic lupus
             erythematosus

          -  Previous history of thromboembolic events e.g., cerebrovascular accident or deep vein
             thrombosis or administration of any antithrombotic or antiplatelet drugs within 7 days
             of study enrollment

          -  Received treatment with any experimental agent within 30 days of study enrollment

          -  Any surgical procedure in the 30 days prior to enrollment

          -  Donated blood within 30 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Lovejoy AE, Reynolds TC, Visich JE, Butine MD, Young G, Belvedere MA, Blain RC, Pederson SM, Ishak LM, Nugent DJ. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006 Jul 1;108(1):57-62. Epub 2006 Mar 23.</citation>
    <PMID>16556896</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2003</study_first_submitted>
  <study_first_submitted_qc>March 19, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2003</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

